Clinical trials: Checkpoint Inhibitor
Immune Checkpoint Inhibitor, Lung Cancer
Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Lung cancer is the leading cause of cancer death worldwide. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of lung cancer over the past 10 years.
- Conditions
- Immune Checkpoint Inhibitor, Lung Cancer, Liver Biomarkers, Transaminases
- Trial name
- HEPATICI (NCT05653531)
- Testing
- Blood sample
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Advanced Solid Tumor, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors.
- Conditions
- Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety
- Trial name
- SCARCE (NCT05915481)
- Testing
- Cadonilimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Graft Rejection, Hepatocellular Carcinoma
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC. The combination of the ICI and other treatment regimens (Anti-VEGF, locoregional therapies et al) produced superior results in patients with…
- Conditions
- Graft Rejection, Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT05913583
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05898256
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Guangxi Medical University
Cervical Cancer, Immune Checkpoint Inhibitor
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study
- Conditions
- Cervical Cancer, Immune Checkpoint Inhibitor, Chemoradiotherapy
- Trial name
- NCT05863260
- Testing
- Treatment Group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Immune Checkpoint Inhibitors, Lung Cancer
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the…
- Trial name
- NCT05288569
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Cancer, Immune Checkpoint Inhibitor
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
Prospective study cohort on patients addressed for suspected cardiovascular event on immune checkpoint inchibitors. Longitudinal prospective single center cohort.
- Conditions
- Cancer, Immune Checkpoint Inhibitor, Cardiovascular Complication, Immune-related Adverse Event
- Trial name
- FAST-TRACK (NCT05799898)
- Testing
- No intervention for research purposes only
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Mutualiste Montsouris
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Non-intervention observation to evaluate the safety and efficacy of immune checkpoint inhibitors alone or combined with molecular targeted drugs / local interventional therapy in patients with advanced liver cancer, and to…
- Trial name
- NCT05609695
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, EGFR Gene Mutation
A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC
Low intensity, intermediate frequency (100-300 kHz) alternating electric fields, also known as Tumor Treating Fields (TTFields) were found to have a profound inhibitory effect on the growth rate of a variety of human cancer…
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor
- Trial name
- NCT05698264
- Testing
- concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment, concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Nir Peled
Immune Checkpoint Inhibitor, Endocrine Toxicity
Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)
Immune checkpoint inhibitor (ICI) includes agents that block cytotoxic T-cell-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1).
- Trial name
- NCT05675111
- Where
- China
- Volunteers
- 12,408 people
- Sponsor
- Nanjing Medical University
Cancer, IMMUNE CHECKPOINT INHIBITOR
Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2
Over the past 20 years, the views and experiences of patients in the field of oncology (through patient-reported outcomes, PROMs) have become increasingly important.
- Conditions
- Cancer, IMMUNE CHECKPOINT INHIBITOR, Quality of Life
- Trial name
- EORTC ICI (NCT05554432)
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Institut Curie
Gemcitabine, Biliary Tract Cancer
The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies
To the patient of terminal biliary malignancy tumor, how should the patient's treatment plan choose ? To address this problem, this study intends to analyze systemic venous gemcitabine-based chemotherapy regimen combined with…
- Conditions
- Gemcitabine, Biliary Tract Cancer, Immune Checkpoint Inhibitors
- Trial name
- NCT05487443
- Testing
- Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First People's Hospital of Hangzhou
NSCLC Stage IV, Checkpoint Inhibitor
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC
This is a phase Ib/IIa, open-label, single center study, aiming to investigate safety and efficacy of nivolumab (administered intravenously) in combination with anlotinib (administered orally) in immunotherapy-treated advanced…
- Trial name
- NCT04507906
- Testing
- Nivolumab Combined with Anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Chest Hospital
Leptomeningeal Metastasis, Immune Checkpoint Inhibitor
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe
- Conditions
- Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin
- Trial name
- NCT05385185
- Testing
- Camrelizumab or envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Medical University
Myocarditis, Immune Checkpoint Inhibitors
Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors
ICI's have become the first-line treatment for patients with various malignancies. Although case studies represent fulminant myocarditis, there is uncertainty in prevalence of subclinical myocardial injury induced by ICI's.
- Conditions
- Myocarditis, Immune Checkpoint Inhibitors, Cardiotoxicity, Myocardial Injury
- Trial name
- MIICI (NCT05349058)
- Testing
- Immune Checkpoint Inhibitors
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Flinders University
Cervical Carcinoma, Chemoradiotherapy
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally…
- Conditions
- Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy
- Trial name
- NCT05311566
- Testing
- Camrelizumab plus Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lei Li
Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical…
- Conditions
- Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy, Recurrent Cervical Carcinoma
- Trial name
- NCT05310305
- Testing
- Radiotherapy for targeted lesions and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy
- Trial name
- NCT05310383
- Testing
- Tislelizumab plus radiotherapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Lei Li
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors
- Trial name
- NCT05290935
- Testing
- Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Lei Li
Plaque, Atherosclerotic, Immune Checkpoint Inhibitors
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
- Conditions
- Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor, Carotid Artery Plaque
- Trial name
- NCT05123287
- Testing
- PD-1 immune checkpoint blockades
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine